Astrotech Corp  (ASTC)
Other Ticker:  
Price: $11.1800 $-0.01 -0.117%
Day's High: $11.26 Week Perf: -1.5 %
Day's Low: $ 10.75 30 Day Perf: 8.23 %
Volume (M): 2 52 Wk High: $ 14.07
Volume (M$): $ 18 52 Wk Avg: $5.53
Open: $10.75 52 Wk Low: $0.31

 Market Capitalization (Millions $) 18
 Shares Outstanding (Millions) 2
 Employees 42
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -9
 Cash Flow (TTM) (Millions $) -22
 Capital Exp. (TTM) (Millions $) 2

Astrotech Corp

Astrotech Corporation (Nasdaq: ASTC) , a Washington corporation organized in 1984, is an Austin, Texas based technology company that has evolved from over 30 years in the human spaceflight, Space Shuttle and Department of Defense (“DOD”) satellite programs. The Company is a leader in the commercialization of space technologies, and we also continuously evaluate potential investment opportunities where we can leverage our significant entrepreneurial experience, operating experience and vast network to add value for our shareholders.

The Company now operates a single reportable business unit, Spacetech, and its efforts are focused on the following:

Working with customers and development partners to satisfy application specific chemical detection objectives using our advanced mass spectrometry technology;

Extending our intellectual property portfolio by enhancing and refining our mass spectrometry technology;

Enabling film restoration, enhancement and digitization using an automated process that revives the original color and removes dust, scratches and defects from film to restore it to its original condition;

Facilitating the shift from 2K resolution to Ultra-High Definition (“UHD”) High Dynamic Range (“HDR”) 4K resolution, the format in which the next generation of digital video content will be delivered to the home; and

Developing next generation vaccines using the unique environment of microgravity.

We are a technology company designed to commercialize space-industry technologies. The substantial majority of operations are related to 1st Detect and the Company is in the process of developing two other business lines.

1st Detect develops, manufactures and sells miniaturized transportable mass spectrometers and related equipment. Mass spectrometers, in general, measure the mass and relative abundance of ions in a sample to create a “mass spectrum.” The resulting mass spectrum is a unique fingerprint that is compared to a reference library of mass spectra to verify the identity of a sample. Mass spectrometers can identify chemicals with more accuracy and precision than competing instruments given their extreme sensitivity and specificity.

1st Detect’s mass spectrometer is a chemical analyzer that provides laboratory quality, real-time analysis. The system is now the platform for the world’s smallest commercially available Gas Chromatograph/Mass Spectrometer (“GC/MS”). The Company’s proprietary technology utilizes advanced low power electronics and miniaturization technologies developed for detecting a wide range of chemicals quickly with very high sensitivity, specificity and reliability. The instrument provides laboratory quality performance in a much smaller footprint and at a much lower price than competing mass spectrometers. The Company has eleven granted U.S. patents, seven granted foreign patents, three pending U.S. patents and two pending foreign patent applications.
Our product portfolio currently consists of the following products:

MMS-1000™ - the MMS-1000™ is a small, low power desktop mass spectrometer designed for the laboratory market. The unique design of this unit enables fast, quality chemical analysis and requires minimal benchtop space (about the size of a shoebox), requires less power than a typical light bulb, and, unlike traditional instruments, requires no consumables or special infrastructure.

OEM-1000 - the OEM-1000 is a mass spectrometer component that drives the MMS-1000™. It is designed to be integrated into a customer’s specific packaging and enclosures, and is well suited to be integrated with application specific sampling or separation technology. A variant, the OEM-1000PI has recently been integrated into a TGA manufactured by RIGAKU Corp. of Tokyo, Japan, one of the leading instrumentation companies in Asia. The integrated instrument named Thermo iMS2 is the world’s first integrated TGA with MS/MS capabilities and will be sold by RIGAKU to the international research and development markets. A further variant of the OEM-1000 has been selected by Battelle, a leading supplier of military chemical detection equipment, for integration into the NGCD, a program under development by the DOD’s Joint Program Executive for Chemical and Biological Defense.

iONTRAC - the iONTRAC is a process analyzer utilizing an enhanced version of our core mass spectrometer technology, which includes the addition and integration of gas chromatography and continuous 24/7 operational features. The iONTRAC provides in-situ real-time monitoring of industrial processes, and we are targeting customers in petrochemical processing, food and beverage manufacturing, critical infrastructure protection and semiconductor clean-room environmental monitoring. The instrument is designed to autonomously monitor processes and to provide reports using industry standard factory management system (“FMS”) infrastructure.

Astrogenetix is a biotechnology company formed to commercialize vaccine targets discovered in the unique environment of microgravity.

Astrogenetix is a biotechnology company formed to commercialize products processed in the unique environment of microgravity. Astrogenetix pursued an aggressive space access strategy to take advantage of the space shuttle program prior to its retirement in 2011. Astrogenetix and the team are currently focused on developing a Salmonella vaccine as part of the ongoing commercialization strategy. We have negotiated a Space Act Agreement with NASA providing for a minimum of twenty-eight additional space flights following the successful filing of the IND application for Salmonella.

Astral Images

Astral provides efficient and high quality film digitization, image correction and enhancement technology. We offer complete systems containing customized off-the-shelf hardware with integrated Astral Images software, standalone software products and scanning or enhancement services. Our two products include:

Astral Black ICE™ - targeted mainly towards the black and white feature film and televisions series digitization and restoration markets, Astral Black ICE™ is a complete system with customized off the shelf hardware with purpose built software and services. Our image correction and enhancement technology is integrated into the scanner while offering high quality real-time results at scan speed.

Astral Color ICE™ - a standalone software solution that can be integrated into most film scanners to enable color image correction and enhancement.

Both Astral Black ICE™ and Astral Color ICE™ provide for significant cost savings over the expensive and labor intensive manual process that has been the industry standard.

   Company Address: 2105 Donley Drive, Suite 100 Austin 78758 TX
   Company Phone Number: 485-9530   Stock Exchange / Ticker: NASDAQ ASTC
   ASTC is expected to report next financial results on September 14, 2023.

Customers Net Income grew by ASTC's Customers Net Profit Margin grew to

16.32 %

14.46 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


Stock Performances by Major Competitors

5 Days Decrease / Increase
A   -6.56%    
BRKA   -6.56%    
DHR        1.7% 
EMR   -3.61%    
HON   -1.82%    
JCI   -2.12%    
• View Complete Report

Agilent Technologies Inc

Reasonable result at Agilent Technologies Inc over the financial second quarter of 2023

Agilent Technologies Inc, a Biotechnology and Pharmaceuticals company has released its financial results for the three months ending April 30, 2023. The company's revenue increased by 6.845% to $1.72 billion as compared to $1.61 billion on a year-over-year basis. Meanwhile, the company's profitability showed significant improvement, with profits rising 12.09% to $1.02 from $0.91 in the prior year reporting season.
However, there was a decrease in revenue by -2.221% from $1.76 billion in the preceding period, and profits also fell by -14.29% from $1.19 per share. Despite these reductions, earnings rose by 10.22% from net earnings of $274.000 million reported in the second quarter of the 2023 earnings season a year ago.

Steris Plc

The Biotechnology and Pharmaceuticals company has failed to turn into profitability despite the epic Surge in revenue in the fourth quarter of 2023

Steris Plc, a leading biotechnology and pharmaceuticals company, has announced a significant increase in revenue for the most recent fiscal period. The company reported a year-on-year revenue rise of 311.172% to $2.94 billion, which is an impressive figure. However, the company slipped into a net loss of $-0.60. This news is significant and has caused some concern among investors and stakeholders.
Compared to the preceding quarter, the income per share fell from $0.56 per share. On the other hand, revenue doubled by a substantial 322.827% from $696.24 million. In the fourth quarter of 2023, Steris Plc posted a net loss of $-90.386 million, as opposed to the net proceeds of $73.623 million recorded in the same quarter a year before. This decline in profits is concerning and indicates a downward trend.

Burzynski Research Institute Inc

The emerging corporation from the Biotechnology and Pharmaceuticals market the Burzynski Research Institute Inc issued the fourth quarter of 2023, results

As a journalist who closely follows the financial performance of various corporations, I find the latest results from Burzynski Research Institute Inc quite intriguing. This small biotech and pharmaceutical firm has reported an operating deficit of $-0.215998 million for the fourth quarter of 2023. While the company has not yet revealed its revenue figures, it is worth comparing these results with the corresponding period from the previous year.
In the fourth quarter of 2022, Burzynski Research Institute Inc had already reported an operating deficit of $-0.131272 million. The fact that the shortfall has further expanded to $-0.216 million in the same quarter of 2023 suggests that the company is going through a turbulent period. However, it's important to note that many businesses face such choppy phases while they try to establish prosperous revenue sources.

Immunovant Inc

The Biotechnology and Pharmaceuticals company announced Revenue of $4.098 million, in the financial fourth quarter of 2023

Immunovant Inc, a clinical stage biopharmaceutical company, has reported their financial results for the fiscal period ending March 31, 2023. According to the report, the company generated revenue of $4.098 million, which is a positive sign.
However, the company also reported a net loss of $59.432 million for the same period, higher than the previous year's loss of $47.171 million. The net loss per share has worsened from $1.43 in the previous fiscal year to $1.71 in this fiscal year, indicating that the company is facing some financial challenges.

Replimune Group Inc

Replimune Group Inc announced operating loss of $-52.995 million, in the fourth quarter of 2023 financial report

Replimune Group Inc is a biotechnology company that focuses on developing cancer therapies based on the use of oncolytic viruses. The company's goal is to develop a range of therapies that can be used in combination with other cancer treatments to improve patient outcomes.
The recent earnings announcement by Replimune Group Inc has raised concerns among investors, who are worried about the company's current financial situation. The $52.995 million operating loss for the most recent fiscal period is a cause for concern, particularly as the company is expected to report further losses in the coming months.


Astrotech's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071